A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Infant Developmental Assessment
Interventions
OTHER

Unintentional exposure in utero

This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).

Trial Locations (8)

16635

Pfizer Investigational Site, Duncansville

33189

Pfizer Investigational Site, Cutler Bay

77065

Pfizer Investigational Site, Houston

84109

Pfizer Investigational Site, Salt Lake City

85282

Pfizer Investigational Site, Tempe

85283

Pfizer Investigational Site, Tempe

92595

Pfizer Investigational Site, Wildomar

38119-5214

Pfizer Investigational Site, Memphis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY